Skip to main content
Guiyang Xintian Pharmaceutical Co.,Ltd. logo

Guiyang Xintian Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 002873 ISIN · CNE100002QB5 LEI · 300300Y5M5RYL4HP2A51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,565 across all filing types
Latest filing 2026-05-13 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002873

About Guiyang Xintian Pharmaceutical Co.,Ltd.

https://www.gyxtyy.com

Guiyang Xintian Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and distribution of proprietary Chinese medicines. The company focuses primarily on gynecological health, urology, and other therapeutic areas. Its core product portfolio includes Kuntai Capsules, used for treating menopausal syndrome; Ningmitai Capsules, indicated for urinary tract infections; and Bitongxiao Granules, used for breast hyperplasia. The firm emphasizes the modernization of Traditional Chinese Medicine (TCM) through rigorous scientific research and standardized production processes. By integrating traditional formulas with modern pharmaceutical technology, the company aims to provide clinical solutions for chronic and common diseases. Its operations encompass the entire value chain from raw material sourcing to clinical application, maintaining a strong presence in the clinical market through a professional academic promotion model.

Recent filings

Filing Released Lang Actions
关于已回购股份出售结果及出售股份比例达1%暨股份变动的公告
Transaction in Own Shares Classification · 91% confidence The document is an official announcement by the company describing the completion of the sale of its repurchased (treasury) shares, detailing the number of shares sold, percentages before and after, transaction prices, regulatory compliance, and effects on share capital. This matches 'Transaction in Own Shares' (POS).
2026-05-13 Chinese
关于完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 87% confidence The document is a corporate announcement regarding completion of industrial and commercial registration changes and issuance of a new business license. It does not include financial statements, earnings information, capital-raising details, management changes, or voting results. It is a standard disclosure under regulatory requirements. This falls under the miscellaneous regulatory filings category (RNS).
2026-05-13 Chinese
关于控股股东部分股份质押展期的公告
Regulatory Filings Classification · 80% confidence The document is a formal stock exchange announcement by a Chinese listed company disclosing the extension of a pledge of shares by its controlling shareholder. It describes a collateral pledge arrangement rather than a change in share ownership ratios, dividend or corporate action like a stock issuance or repurchase. This does not constitute an earnings release, report publication, insider trade, capital raising by the company itself, or any M&A/financing transaction in the company’s own shares. It is best treated as a regulatory/compliance disclosure under the generic “Regulatory Filings” category (RNS).
2026-05-11 Chinese
关于出售已回购股份进展及首次出售回购股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress and details of selling previously repurchased shares. It includes specific dates, quantities, prices, and regulatory references related to the sale of treasury shares. The content focuses on the sale of own shares and compliance with stock exchange rules. It is not a full financial report, earnings release, or management discussion, but rather a disclosure about share transactions by the company itself. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and it contains detailed transaction information, not just a notice or link to a report, so it is not an RPA or RNS.
2026-05-07 Chinese
关于控股股东拟减持公司股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a planned reduction in shareholding by the controlling shareholder of the company. It details the shareholder's intention to sell a specific number of shares within a defined period, the reasons for the reduction, the methods of sale, and compliance with relevant regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but an announcement about a shareholding change by a major shareholder. This fits the category of Major Shareholding Notification (MRQ). The document length is 3622 characters, which is consistent with an announcement rather than a full report.
2026-05-07 Chinese
董事会关于独立董事独立性情况评估的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors evaluating the independence of the company's independent directors. It discusses compliance with regulatory guidelines on independent directors, their independence status, and the board's opinion on their independence. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is a governance-related report focusing on board and director information, specifically about independent directors' independence assessment. Therefore, it fits best under Board/Management Information (MANG). The document length is short but contains substantive content about board evaluation, not just an announcement or certification, so it is not RNS or RPA.
2026-03-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.